OSTX Latest Press Releases

-- November 10, 2026 --

OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma Newsfile 8:17 AM

-- November 5, 2026 --

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial Newsfile 8:00 AM

-- October 19, 2026 --

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million Newsfile 8:30 AM

-- October 8, 2026 --

Rubenstein Public Relations Named Agency of Record for OS Therapies Globe Newswire 9:22 AM

-- October 7, 2026 --

OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma Newsfile 8:32 AM

-- October 6, 2026 --

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial Newsfile 8:30 AM

-- October 1, 2026 --

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer Newsfile 8:30 AM

-- September 24, 2026 --

OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) Newsfile 8:56 AM

OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) Newsfile 8:24 AM

-- September 21, 2026 --

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis Newsfile 6:30 AM

-- September 17, 2026 --

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program Newsfile 7:14 AM

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program Newsfile 6:02 AM

-- September 15, 2026 --

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing Newsfile 7:46 AM

-- September 8, 2026 --

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial Newsfile 6:00 AM

-- September 2, 2026 --

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance Newsfile 7:21 AM

-- August 17, 2026 --

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates Newsfile 7:40 AM

-- August 13, 2026 --

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma Newsfile 8:45 AM

-- July 8, 2026 --

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program Newsfile 9:02 AM

-- July 6, 2026 --

OS Therapies Third Quarter 2026 Corporate Outlook Newsfile 9:01 AM

-- July 2, 2026 --

OS Therapies Appoints Dr. Craig Eagle to Board of Directors Newsfile 7:33 AM

-- June 30, 2026 --

OS Therapies Provides U.S. Regulatory Update Newsfile 7:41 AM

-- June 26, 2026 --

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma Newsfile 7:41 AM

Market Data Delayed 15 Minutes